Overview

A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinical management of cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Antibodies, Monoclonal